BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29924913)

  • 21. Antitumor effect of miR-27b-3p on lung cancer cells via targeting Fzd7.
    Sun Y; Xu T; Cao YW; Ding XQ
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4113-4123. PubMed ID: 29028088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ginsenoside-Rb1 promotes adipogenesis through regulation of PPARĪ³ and microRNA-27b.
    Chan LS; Yue PY; Kok TW; Keung MH; Mak NK; Wong RN
    Horm Metab Res; 2012 Oct; 44(11):819-24. PubMed ID: 22893262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
    Yan X; Zhao J; Zhang R
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells.
    Jin Y; Wang H; Zhu Y; Feng H; Wang G; Wang S
    Eur J Pharmacol; 2020 Jul; 878():173105. PubMed ID: 32278855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
    BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1.
    Zhang W; Ji W; Zhao X
    BMC Cancer; 2019 Nov; 19(1):1093. PubMed ID: 31718618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2.
    Carina V; Zito G; Pizzolanti G; Richiusa P; Criscimanna A; Rodolico V; Tomasello L; Pitrone M; Arancio W; Giordano C
    Thyroid; 2013 Jul; 23(7):829-37. PubMed ID: 23301671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a.
    Pacifico F; Crescenzi E; Mellone S; Iannetti A; Porrino N; Liguoro D; Moscato F; Grieco M; Formisano S; Leonardi A
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1421-30. PubMed ID: 20061417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of nutraceuticals on anaplastic thyroid cancer cells.
    Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism.
    Pan C; Wang X; Shi K; Zheng Y; Li J; Chen Y; Jin L; Pan Z
    PLoS One; 2016; 11(5):e0152090. PubMed ID: 27138141
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Xu J; Lv S; Hou Y; Xu K; Sun D; Zheng Y; Zhang Z; Li X; Li Y; Chi G
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29187585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
    Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
    Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.
    Ma L; Cheng Q
    Biochem Biophys Res Commun; 2018 Apr; 498(4):912-917. PubMed ID: 29534964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. microRNAs: Key regulators of chemotherapy response and metastatic potential via complex control of target pathways in esophageal adenocarcinoma.
    Matuszcak C; Lindner K; Eichelmann AK; Hussey DJ; Haier J; Hummel R
    Surg Oncol; 2018 Sep; 27(3):392-401. PubMed ID: 30217293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1.
    Zhao X; Jin Y; Li L; Xu L; Tang Z; Qi Y; Yin L; Peng J
    Pharmacol Res; 2019 Aug; 146():104276. PubMed ID: 31112750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer.
    Shen SJ; Song Y; Ren XY; Xu YL; Zhou YD; Liang ZY; Sun Q
    Front Oncol; 2020; 10():1371. PubMed ID: 32850439
    [No Abstract]   [Full Text] [Related]  

  • 39. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARĪ³-dependent manner in leukemia cells.
    Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
    Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance.
    Li R; Xu T; Wang H; Wu N; Liu F; Jia X; Mi J; Lv J; Gao H
    Biochem Biophys Res Commun; 2019 Nov; 519(2):358-365. PubMed ID: 31519321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.